Exclusive: Tome Biosciences is floundering, sources say

Just nine months after launching with $213 million in funding, several sources spoke of a grave future for the company

Log In    Subscribe EXCLUSIVE   Tome Biosciences, once a high-flying gene-editing startup, is floundering By Jason Mast and Allison DeAngelis Adobe Gene-editing startup Tome Biosciences is floundering, just nine months after launching with $213 million in funding, according to several sources with direct knowledge of the matter.   One person with knowledge of the situation told STAT that Tome is winding down operations altogether and seeking a buyer by Nov. 1. Another source reported that there are still options on the table to keep the biotech running. Both spoke on condition of anonymity to be able to speak candidly. READ MORE Sign up for Health Care Inc. Unpacking the business — and secretive inner workings — of the U.S. health care industry. In Case You Missed It 1   AI drug firm Recursion seeks to move from survival to industry domination By Allison DeAngelis 2   What to know about Alnylam's upcoming readout on its heart drug By Elaine Chen, Andrew Joseph, and Adam Feuerstein 3   Does Ozempic increase the risk of suicidal thoughts? By Elaine Chen 4   Gene therapy pioneer Jim Wilson believes he can commercialize rare-disease drugs in a tough climate By Jonathan Wosen Don't miss out on another STAT Investigation Unlock the world of health and medicine with a subscription to STAT+ Learn more STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences • Contact Us • Advertise with Us